Fundraising FoxSmartHealth Catalyzer — Full Portfolio
7 tracked investments · listed companies and verified rows first
A biotech company focused on microbiome and metabolomics research for gastrointestinal health applications, with leadership and scientific advisory rooted in academic medicine and regulatory expertise.
BiotechDigital HealthHealthtechMedical DevicesIllinois, US
Joseph Francis Pierre(Director)Brian Yoor(Director)Eugene Chang(Director)Jaime Contreras(Director)John C. Alverdy(Director)Peter Farmakis(Executive Officer, Director)
Created a point-of-care diagnostic platform for specialty physician and oncologist offices enabling rapid cancer diagnosis during patient visits.
Developing a first-in-class smartlens system for glaucoma treatment that rapidly reduces intraocular pressure in patients.
Co-investorsElevate Ventures
Cadenza Bio develops small-molecule drugs for oral administration to treat demyelinating and inflammatory diseases.
BiotechFemTechMedical DevicesYukon, US
Carol Curtis, PhD(Chief Executive Officer, Founder)Elaine Hamm, PhD(Chief Operating Officer, Founder)John Katzenellenbogen, PhD(Scientific Founder)Seema Tiwari-Woodruff, PhD(Scientific Founder)Elaine Hamm(Executive Officer, Director)Carol Curtis(Executive Officer, Director)in
Co-investorsCortado VenturesIllinois VenturesOklahoma Life SciencePlains Ventures
The company develops cancer immunotherapy treatments.
AI & Machine LearningBiotechHealthtech
Rich Johnson(Co-Founder, VP of Development)inDominique Kendrick(Co-Founder, SVP of Regulatory Affairs)Prof. James Moon(Co-Founder, Chief Scientific Officer)Prof. Yu Leo Lei(Co-Founder, Clinical and Pre-Clinical Advisor)Robert Petit(Co-Founder, Clinical and Pre-Clinical Advisor)inMatthew Martin(Co-Founder, Partner at Pathway Bioventures)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BEST OF THE BIOMIDWESTDelphian Website
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.